Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature

Constantinos Savva(University of Nottingham), Kamal Chokkalingam(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Jason Adhikaree(University of Nottingham)
Journal of Diabetes & Metabolic Disorders
March 22, 2019
10.1007/s40200-019-00398-y
Cited by 23

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
|The Lancet Oncology|2015|282